Login to Your Account



La Jolla's Riquent Approvable Letter: Finished Study Needed

By Karen Pihl-Carey


Monday, October 18, 2004
La Jolla Pharmaceutical Co. received an approvable letter for its lupus drug candidate Riquent that requires the completion of another clinical study for final approval. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription